ArticleBMC infectious diseases2026
COVID-19 vaccine immunogenicity in Mongolian adults with and without chronic hepatitis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMongolia has a high prevalence of liver disease from chronic viral hepatitis infections, which can compromise the immune response. It is unclear whether people with chronic liver disease produce a robust antibody response to the COVID-19 vaccines. We investigated whether the antibody response to the COVID-19 booster vaccination differed between those with and without chronic viral hepatitis from multiple viral types.
methodsParticipants from Mongolia were recruited to the International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE). Demographic information was recorded and participants’ SARS-CoV2 anti-Spike antibody levels were measured at visit 1 (prior to administration of booster vaccine at baseline) and visit 2 (approximately 2 +/-1 months after booster vaccination). We used linear regression to determine if the anti-Spike antibody responses differed between participants with and without different types of chronic viral hepatitis infections.
resultsOverall, there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis, a result suggesting that COVID-19 vaccine booster immunogenicity is not affected by chronic hepatitis. Participants with chronic HCV infection produced a robust antibody response, but based on our linear regression analysis, this response seemed to wane faster than in participants without chronic viral hepatitis.
conclusionsOur finding that there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis adds to the evidence that the COVID-19 vaccines are immunogenic in people with chronic viral hepatitis, including in those with HBV/HDV coinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.